MA34225B1 - Préparation stable de mia/cd-rap - Google Patents

Préparation stable de mia/cd-rap

Info

Publication number
MA34225B1
MA34225B1 MA35359A MA35359A MA34225B1 MA 34225 B1 MA34225 B1 MA 34225B1 MA 35359 A MA35359 A MA 35359A MA 35359 A MA35359 A MA 35359A MA 34225 B1 MA34225 B1 MA 34225B1
Authority
MA
Morocco
Prior art keywords
rap
mia
amino acid
preparation
preparation according
Prior art date
Application number
MA35359A
Other languages
English (en)
Inventor
Klaus Hellerbrand
Rainer Sigl
Original Assignee
Scil Technology Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Technology Gmbh filed Critical Scil Technology Gmbh
Publication of MA34225B1 publication Critical patent/MA34225B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des préparations aqueuses stables contenant au moins 5 mg/mL de CD-RAP et un acide aminé chargé, ledit acide aminé présentant de préférence une charge nette à un pH compris entre 6 et 8. Les ingrédients de la préparation selon l'invention confèrent de préférence une stabilité pendant des cycles répétés de gel-dégel. Dans un aspect préféré, la préparation selon l'invention est destinée à être utilisée dans des traitements, de préférence dans le traitement des troubles inflammatoires, de préférence l'arthrose. L'invention concerne encore un kit contenant cette préparation.
MA35359A 2010-04-27 2011-04-27 Préparation stable de mia/cd-rap MA34225B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10161160 2010-04-27
PCT/EP2011/056622 WO2011134979A2 (fr) 2010-04-27 2011-04-27 Préparation stable de mia/cd-rap

Publications (1)

Publication Number Publication Date
MA34225B1 true MA34225B1 (fr) 2013-05-02

Family

ID=43806879

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35359A MA34225B1 (fr) 2010-04-27 2011-04-27 Préparation stable de mia/cd-rap

Country Status (20)

Country Link
US (2) US9511116B2 (fr)
EP (1) EP2563809B1 (fr)
JP (2) JP2013525406A (fr)
KR (1) KR101880905B1 (fr)
CN (1) CN102869679B (fr)
AU (1) AU2011247659B2 (fr)
BR (1) BR112012027361A2 (fr)
CA (1) CA2792965A1 (fr)
CL (1) CL2012002948A1 (fr)
CO (1) CO6592098A2 (fr)
HK (1) HK1179273A1 (fr)
IL (1) IL222712B (fr)
MA (1) MA34225B1 (fr)
MX (1) MX344732B (fr)
MY (1) MY160916A (fr)
NZ (1) NZ601927A (fr)
RU (2) RU2588658C2 (fr)
SG (3) SG10201908916UA (fr)
WO (1) WO2011134979A2 (fr)
ZA (1) ZA201206235B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012027361A2 (pt) * 2010-04-27 2021-04-27 Scil Technology Gmbh formulação mia/cd-rap estável.
WO2014098232A1 (fr) * 2012-12-21 2014-06-26 Yamashita Chikamasa Composition pharmaceutique comprenant un inhibiteur de kinase pi3, composition pharmaceutique comprenant un composé qui agit sur un récepteur de vitamine d, composition lyophilisée, procédé de production de composition lyophilisée et composition pharmaceutique destinée à être administrée par voie transpulmonaire
JP6707469B2 (ja) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
EP3350204A2 (fr) 2015-09-18 2018-07-25 BioNet Pharma GmbH Amélioration de l'expression et du pliage dans le processus de fabrication de cd-rap en utilisant une protéine du précurseur de cd-rap
CA3030422C (fr) * 2016-07-13 2021-10-26 Reform Biologics, Llc Excipients stabilisants pour formulations de proteines therapeutiques
CN109996805B (zh) 2016-11-29 2023-03-28 丝芭博株式会社 蛋白质组合物、其制造方法和热稳定性提高方法
JP7179717B2 (ja) * 2017-03-31 2022-11-29 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
KR20190066941A (ko) 2017-12-06 2019-06-14 주식회사 에코에너젠 반도체 제조 공정의 복합오염물질 저감 장치
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
KR102427935B1 (ko) 2022-05-23 2022-08-03 주식회사 동우이엔티 습식 스크러버를 포함한 입자상 및 가스상 오염물질이 혼합된 복합가스의 동시 처리가 가능한 습식 전기집진시스템

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54147916A (en) * 1978-05-12 1979-11-19 Sumitomo Chem Co Ltd Preparation of urokinase injection
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4374763A (en) * 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
EP0158487B1 (fr) 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Composition stable d'interleukine-2
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
JP3435163B2 (ja) 1993-07-20 2003-08-11 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 黒色腫阻害蛋白質
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP1516628B1 (fr) * 1995-07-27 2013-08-21 Genentech, Inc. Formulation de protéine stabile, lyophilisée et isotonique
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
WO2000012762A1 (fr) 1998-09-01 2000-03-09 Millennium Pharmaceuticals, Inc. Nouvelle proteine liee a la proteine inhibitrice des melanomes et utilisation de cette nouvelle proteine
EP1025871A1 (fr) 1999-01-28 2000-08-09 F. Hoffmann-La Roche Ag Utilisation d'un facteur à activité inhibitrice du mélanome pour la réparation de cartilage et des os
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
RU2197238C2 (ru) * 1999-11-22 2003-01-27 Российский научный центр "Восстановительная травматология и ортопедия" им. академика Г.А. Илизарова Способ профилактики и лечения остеоартроза, средство для его осуществления и способ получения средства для лечения остеоартроза
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
AU2001232967A1 (en) 2000-01-25 2001-08-07 Hyseq, Inc. Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
MXPA02008889A (es) 2000-03-23 2003-04-25 Akzo Nobel Nv Uso de mia en inmunoterapia.
DK1450847T3 (da) * 2001-11-13 2010-12-13 Genentech Inc Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
DE60322513D1 (de) * 2002-02-27 2008-09-11 Immunex Corp Stabilisierte TNFR-Fc Formulierung mit Arginin
AU2003259696A1 (en) * 2002-08-08 2004-02-25 Nuvelo, Inc. Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
DE10360483B4 (de) 2003-12-22 2007-11-15 Scil Proteins Gmbh Expressionsvektor und dessen Verwendung
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
WO2008040556A1 (fr) * 2006-10-06 2008-04-10 Scil Technology Gmbh Formation de vésicules reconstituées séchées pour application pharmaceutique
AU2008204901A1 (en) * 2007-01-09 2008-07-17 Wyeth Anti-IL-13 antibody formulations and uses thereof
BR112012027361A2 (pt) * 2010-04-27 2021-04-27 Scil Technology Gmbh formulação mia/cd-rap estável.

Also Published As

Publication number Publication date
CO6592098A2 (es) 2013-01-02
US9511116B2 (en) 2016-12-06
AU2011247659B2 (en) 2014-07-24
ZA201206235B (en) 2021-04-28
RU2739078C2 (ru) 2020-12-21
SG10201502398RA (en) 2015-05-28
SG183561A1 (en) 2012-09-27
HK1179273A1 (zh) 2013-09-27
IL222712B (en) 2018-02-28
EP2563809A2 (fr) 2013-03-06
JP2013525406A (ja) 2013-06-20
JP2016034958A (ja) 2016-03-17
MY160916A (en) 2017-03-31
BR112012027361A2 (pt) 2021-04-27
MX2012012115A (es) 2013-01-29
US9907829B2 (en) 2018-03-06
NZ601927A (en) 2013-07-26
WO2011134979A9 (fr) 2012-08-16
CN102869679B (zh) 2015-11-25
KR20130086531A (ko) 2013-08-02
US20130137639A1 (en) 2013-05-30
CL2012002948A1 (es) 2013-02-15
SG10201908916UA (en) 2019-11-28
CN102869679A (zh) 2013-01-09
KR101880905B1 (ko) 2018-07-23
MX344732B (es) 2017-01-04
IL222712A0 (en) 2012-12-31
RU2016118646A3 (fr) 2019-06-20
JP6078129B2 (ja) 2017-02-08
CA2792965A1 (fr) 2011-11-03
RU2016118646A (ru) 2018-11-02
WO2011134979A2 (fr) 2011-11-03
US20170042971A1 (en) 2017-02-16
WO2011134979A3 (fr) 2012-06-14
RU2588658C2 (ru) 2016-07-10
RU2012144771A (ru) 2014-06-10
EP2563809B1 (fr) 2020-04-01
AU2011247659A1 (en) 2012-09-06

Similar Documents

Publication Publication Date Title
MA34225B1 (fr) Préparation stable de mia/cd-rap
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA29836B1 (fr) Proteines de fusion avec l'albumine
EP4331668A3 (fr) Composés pour inhiber nlrp3 et leurs utilisations
MA33295B1 (fr) Nouvelle formulation de diclofénac
EA201200490A1 (ru) Стабильный совместный состав, содержащий хиалуронидазу и иммуноглобулин, и способы его применения
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
MA44674B1 (fr) Inhibiteurs de bromodomaine
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
CA2332616A1 (fr) Compositions pharmaceutiques, hygieniques et/ou cosmetiques contenant del'eau de mer et leurs utilisations
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
EA200400162A1 (ru) N-(3-амино-2-гидроксипропил)замещенные алкиламидные соединения
MA33299B1 (fr) Nouvelle formulation de naproxène
HUP0400368A2 (hu) Oxitocin agonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk szexuális zavarok kezelésére
EA201590509A1 (ru) Жидкая композиция, содержащая соединение, нейтрализующее gm-csf
BRPI0720230B8 (pt) formulação nutricional oralmente administrável, uso da formulação, e, composição
MA27474A1 (fr) Vaccin
EA202192291A1 (ru) Композиция, содержащая стабильную в течение длительного времени живую фекальную микробиоту
RU2009127858A (ru) Фармацевтическая композиция, включающая алискирен и авосентан
WO2020044114A3 (fr) Composition pharmaceutique de méthotrexate
FR3094378B1 (fr) Traitement des maladies respiratoires avec la bacterie lactobacillus animalis
ES2310072A1 (es) Acevos peptidos determinantes antigenicos t colaboradores (dth).
UA53379U (ru) Суспензионный крем для лечения воспалительных стоматологических заболеваний
RU2311802C2 (ru) Биологически активная добавка на основе растительных экстрактов с производными l-карнитина
FR3115680B1 (fr) Compositions pour le traitement du psoriasis.